Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Foreign investors buy UK firms at fastest pace since 2007

Tue, 24th Mar 2015 15:02

* UK acquisitions by foreign buyers total $48 bln year todate

* Highest since 2007 even if bid for O2 is excluded

* Weaker pound, better growth lure U.S. buyers

* Political uncertainty fails to dampen appetite

By Francesco Canepa

LONDON, March 24 (Reuters) - Foreign investors are snappingup British companies at the fastest pace in eight years as anunusual combination of stronger economic growth and a weakcurrency lures U.S. buyers despite political uncertainty.

Investors appear relatively unconcerned about the risk ofinstability after a general election on May 7 or doubts aboutBritain's future in the European Union. Even excluding a $15billion bid by Hutchison Whampoa for O2's UKoperations, inbound mergers & acquisitions activity so far thisyear is at its highest since 2007, Thomson Reuters data showed.

The total value of bids and completed deals in the period is$33 billion, including debt taken on by buyers. The figure risesto $48 billion when Hong Kong-based Hutchison's bid for themobile phone operator is included.

This reverses a seven-year decline and contrasts to a fallin inbound M&A activity in the euro zone and United States.

It also confounds expectations of dwindling M&A before theelections, in which opinion polls suggest no party will win amajority. This raises the possibility of an unstable coalitionor minority government propped up by smaller parties such as thepro-independence Scottish nationalists.

On top of this, the ruling Conservatives have promised areferendum within two years on whether Britain should leave theEU, should they be re-elected.

Many British business leaders are worried by the prospect.The chairman of insurer Standard Life said on Tuesday it would be disastrous for the country and London's financialcentre if Britain were to leave the EU single market.

However, bankers say U.S. investors are being attracted bysterling's weakness against the dollar - which makes Britishtargets cheaper for them - even though the economy is buoyant.

"The UK is at the forefront because the economy, aside fromthe uncertainty around the elections, is an attractive marketwith good growth dynamics," said Dirk Albersmeier, co-head ofM&A for Europe, the Middle East and Africa at JP Morgan.

With the Bank of England expected to keep interest ratesultra low for another year, the pound has fallen 13 percentagainst the dollar since July and is now hovering just above afive-year low. At the same time, official economic growthforecasts were upgraded last week to 2.5 percent this year and2.3 percent in 2016.

VALUATIONS BOOST

Valuations have provided a further boost. UK shares trade ata 10 percent discount to their U.S. counterparts based on theratio between price and expected earnings, Datastream datashowed.

Inbound M&A activity in Britain had been falling since 2007,data from the Office for National Statistics showed, partly dueto the pound's recovery against the euro since 2009.

This year's increase has been driven by 73 small andmid-sized acquisitions by U.S. buyers, such as drinks can makerBall Corp's $8.6 billion move for rival Rexam and a $2.8 billion bid by Verisk Analytics for energyconsultancy Wood Mackenzie.

These deals have more than offset a drying up of last year'sstream of large bids which were partly motivated by lowercorporate tax rates in Britain than in the United States, suchas Pfizer's abandoned attempt to buy fellowpharmaceutical group AstraZeneca.

Such bids have been curbed by a tightening of U.S. tax rulesand worries about possible fiscal changes in Britain after theelections.

As the economic recovery picks up pace, sectors which dependon growth are playing a larger role in M&A, joining defensivesectors such as healthcare and telecommunications, media andtechnology (TMT), where activity has been high for some time.

Aside from the telecoms and materials sectors, where theamount was skewed by the O2 and Rexam bids, inbound M&A activitythis year has been at its highest in the consumer goods sectorand industrial sectors, the data showed.

This marks a change from the previous year, when real estatedominated, with financials and high tech a distant second andthird, respectively.

"Activity is likely to be more broad-based than last year,"said Wilhelm Schulz, head of M&A for Europe, the Middle East andAfrica at Citi. "I expect this year we will see activity inhealthcare, TMT, industrials, chemicals and consumer products." (Additional reporting by Anjuli Davies and Freya Berry; editingby David Stamp)

More News
11 Apr 2024 18:51

AstraZeneca CEO could earn 19 million pounds as pay measure clears opposition

Policy approved with two-third of votes in favour

*

Read more
11 Apr 2024 17:13

FTSE 100 edges lower as financials drag

Lok'nStore surges to all-time high after buyout by Shurgard

*

Read more
11 Apr 2024 17:07

Banks weigh down Europe's STOXX 600 after ECB signals rate cuts

Outlook hike sends Ambu shares up

*

Read more
11 Apr 2024 15:56

London close: Stocks finish lower as ECB stands pat

(Sharecast News) - London's stock markets finished in negative territory on Thursday, as investors reacted to the European Central Bank's latest policy announcement and a producer price index release in the United States.

Read more
11 Apr 2024 11:50

LONDON MARKET MIDDAY: Europe takes hit on nerves ahead of ECB decision

(Alliance News) - European equities sunk lower at midday on Thursday, with sentiment hurt by hotter-than-expected inflation from the US crushing hopes of interest rate cuts.

Read more
11 Apr 2024 08:56

TOP NEWS: Astra plans 7% dividend hike for 2024 after no rise in 2023

(Alliance News) - AstraZeneca PLC said it intends to raise its annualised dividend for 2024, citing confidence in its business performance and cash generation.

Read more
11 Apr 2024 08:54

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

Read more
11 Apr 2024 07:49

LONDON BRIEFING: Astra promises dividend hike; Darktrace ups guidance

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye the latest interest rate decision from the European Central Bank, a day after a hotter-than-expected US inflation reading.

Read more
11 Apr 2024 07:20

AstraZeneca to hike 2024 dividend by 7%

(Sharecast News) - Biopharma giant AstraZeneca has announced that it will increase its annual dividend by 7%, which the board said demonstrates its confidence in the company's performance and cash generation.

Read more
8 Apr 2024 08:36

TOP NEWS: AstraZeneca hails neurological data for Ultomiris, Soliris

(Alliance News) - AstraZeneca PLC on Monday said long-term data in generalised myasthenia gravis will underscore the "vital role" of its Ultomiris and Soliris antibodies in the treatment landscape.

Read more
8 Apr 2024 07:43

LONDON BRIEFING: Astra hails neurology data; CVS flags cyberattack

(Alliance News) - London's FTSE 100 is called to open a touch higher on Monday, ahead of an interest rate decision in the eurozone and a US inflation reading later in the week.

Read more
8 Apr 2024 07:02

AstraZeneca's Enhurtu cancer gets US green light for adult patients

(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu cancer drug has been approved in the US for adult patients with unresectable or metastatic solid tumours who have received prior systemic treatment and have no satisfactory alternative options.

Read more
8 Apr 2024 06:53

TOP NEWS: AstraZeneca's, Daiichi's Enhertu receives US FDA approval

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Saturday announced that the US Food & Drug Administration has approved their cancer drug conjugate for patients with metastatic HER2-positive solid tumours.

Read more
5 Apr 2024 09:42

AstraZeneca makes "breakthrough" in treating small cell lung cancer

(Alliance News) - AstraZeneca PLC on Friday reported positive results relating to its Imfinzi cancer treatment in phase III trials.

Read more
5 Apr 2024 07:50

LONDON BRIEFING: Shell to book USD600 million first-quarter write-off

(Alliance News) - London's FTSE 100 is called to open lower on Friday, with hawkish remarks from Federal Reserve policymakers and fears of ratcheting Middle East tensions giving investors little to cheer about ahead of the latest US jobs data.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.